ARROWHEAD PHARMACEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Nov 26, 2024
ARWR$49.24-15.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 11. EXECUTIVE COMPENSATION
The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Executive Compensation.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.